Jill Slansky
Concepts (322)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cancer Vaccines | 14 | 2021 | 173 | 2.800 |
Why?
| | Receptors, Antigen, T-Cell | 15 | 2023 | 720 | 2.500 |
Why?
| | CD8-Positive T-Lymphocytes | 19 | 2024 | 917 | 2.430 |
Why?
| | Antigens, Neoplasm | 13 | 2023 | 322 | 1.970 |
Why?
| | Neoplasms | 13 | 2023 | 2666 | 1.930 |
Why?
| | T-Lymphocytes | 14 | 2023 | 1999 | 1.880 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 5 | 2023 | 210 | 1.690 |
Why?
| | Vaccines, Subunit | 4 | 2013 | 49 | 1.170 |
Why?
| | T-Lymphocytes, Cytotoxic | 7 | 2022 | 173 | 0.970 |
Why?
| | Peptides | 8 | 2023 | 986 | 0.960 |
Why?
| | Granzymes | 2 | 2024 | 49 | 0.960 |
Why?
| | Epitopes, T-Lymphocyte | 6 | 2012 | 187 | 0.930 |
Why?
| | Mice, Inbred BALB C | 18 | 2021 | 1271 | 0.760 |
Why?
| | Leukemia | 1 | 2024 | 238 | 0.740 |
Why?
| | Immunotherapy | 8 | 2021 | 647 | 0.730 |
Why?
| | Lymphocyte Activation | 11 | 2019 | 1150 | 0.710 |
Why?
| | Tumor Escape | 3 | 2019 | 42 | 0.700 |
Why?
| | Baculoviridae | 3 | 2009 | 44 | 0.660 |
Why?
| | Antigen Presentation | 6 | 2018 | 216 | 0.650 |
Why?
| | Neoplasms, Experimental | 2 | 2021 | 176 | 0.650 |
Why?
| | Tumor Microenvironment | 7 | 2025 | 682 | 0.640 |
Why?
| | Immunogenetic Phenomena | 1 | 2019 | 7 | 0.620 |
Why?
| | Immunomodulation | 1 | 2020 | 98 | 0.620 |
Why?
| | Peptide Library | 4 | 2013 | 88 | 0.620 |
Why?
| | Insecta | 3 | 2009 | 64 | 0.600 |
Why?
| | Epitopes | 2 | 2020 | 481 | 0.590 |
Why?
| | Histocompatibility Antigens Class I | 6 | 2019 | 203 | 0.580 |
Why?
| | Major Histocompatibility Complex | 4 | 2008 | 231 | 0.570 |
Why?
| | Animals | 47 | 2025 | 37011 | 0.570 |
Why?
| | H-2 Antigens | 5 | 2008 | 115 | 0.560 |
Why?
| | Mice | 34 | 2025 | 17843 | 0.540 |
Why?
| | Alternative Splicing | 1 | 2019 | 227 | 0.530 |
Why?
| | Gene Expression Regulation, Neoplastic | 4 | 2019 | 1402 | 0.490 |
Why?
| | Autoimmunity | 2 | 2020 | 907 | 0.480 |
Why?
| | Neoplasm Proteins | 2 | 2018 | 433 | 0.450 |
Why?
| | Immune Tolerance | 3 | 2025 | 362 | 0.450 |
Why?
| | Colorectal Neoplasms | 5 | 2019 | 799 | 0.450 |
Why?
| | Vaccines | 2 | 2010 | 411 | 0.450 |
Why?
| | Up-Regulation | 3 | 2019 | 846 | 0.440 |
Why?
| | Antigens | 3 | 2019 | 358 | 0.440 |
Why?
| | Breast Neoplasms | 4 | 2025 | 2249 | 0.430 |
Why?
| | Cytotoxicity, Immunologic | 6 | 2024 | 225 | 0.430 |
Why?
| | CD4-Positive T-Lymphocytes | 3 | 2019 | 1092 | 0.400 |
Why?
| | Colonic Neoplasms | 3 | 2012 | 258 | 0.400 |
Why?
| | Allergy and Immunology | 1 | 2013 | 43 | 0.390 |
Why?
| | Complementarity Determining Regions | 1 | 2012 | 51 | 0.380 |
Why?
| | Antigenic Variation | 1 | 2011 | 10 | 0.370 |
Why?
| | B-Lymphocytes | 1 | 2017 | 847 | 0.370 |
Why?
| | Moloney murine leukemia virus | 1 | 2011 | 13 | 0.370 |
Why?
| | Viral Envelope Proteins | 1 | 2011 | 84 | 0.350 |
Why?
| | B7-H1 Antigen | 2 | 2025 | 218 | 0.330 |
Why?
| | Cell Cycle Proteins | 6 | 1997 | 614 | 0.330 |
Why?
| | Carrier Proteins | 6 | 1997 | 770 | 0.320 |
Why?
| | Histocompatibility Antigens | 2 | 2020 | 107 | 0.320 |
Why?
| | DNA-Binding Proteins | 9 | 2018 | 1507 | 0.300 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2017 | 1079 | 0.300 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 2 | 2022 | 337 | 0.290 |
Why?
| | Mice, Transgenic | 6 | 2023 | 2182 | 0.290 |
Why?
| | Autoimmune Diseases | 1 | 2012 | 459 | 0.280 |
Why?
| | Tetrahydrofolate Dehydrogenase | 4 | 1997 | 23 | 0.280 |
Why?
| | Inflammation | 4 | 2020 | 2837 | 0.270 |
Why?
| | Cross Reactions | 2 | 2020 | 133 | 0.260 |
Why?
| | Vaccination | 3 | 2010 | 1398 | 0.250 |
Why?
| | Liver Neoplasms | 4 | 2020 | 786 | 0.250 |
Why?
| | Lung Neoplasms | 2 | 2017 | 2494 | 0.240 |
Why?
| | Triple Negative Breast Neoplasms | 2 | 2019 | 202 | 0.240 |
Why?
| | Flow Cytometry | 6 | 2016 | 1185 | 0.230 |
Why?
| | Semaphorins | 1 | 2025 | 32 | 0.230 |
Why?
| | Histocompatibility Antigens Class II | 2 | 2003 | 368 | 0.230 |
Why?
| | Cell Line, Tumor | 10 | 2025 | 3420 | 0.230 |
Why?
| | Antigens, CD | 3 | 2025 | 524 | 0.220 |
Why?
| | Humans | 36 | 2025 | 137514 | 0.220 |
Why?
| | Mammary Glands, Animal | 1 | 2025 | 129 | 0.220 |
Why?
| | Disease Models, Animal | 3 | 2021 | 4295 | 0.220 |
Why?
| | Graft Rejection | 2 | 2007 | 623 | 0.220 |
Why?
| | Listeria monocytogenes | 3 | 2011 | 126 | 0.200 |
Why?
| | Lymphocyte Count | 4 | 2017 | 150 | 0.200 |
Why?
| | Models, Biological | 1 | 2010 | 1775 | 0.200 |
Why?
| | Amino Acid Substitution | 2 | 2020 | 309 | 0.190 |
Why?
| | Transcription Factors | 6 | 1997 | 1717 | 0.190 |
Why?
| | Female | 23 | 2025 | 73162 | 0.180 |
Why?
| | Aging | 2 | 2011 | 1866 | 0.180 |
Why?
| | Base Sequence | 7 | 2016 | 2180 | 0.180 |
Why?
| | Histocompatibility Antigen H-2D | 4 | 2022 | 21 | 0.180 |
Why?
| | Dendritic Cells | 3 | 2014 | 488 | 0.180 |
Why?
| | Receptor-CD3 Complex, Antigen, T-Cell | 1 | 2000 | 9 | 0.170 |
Why?
| | Heterografts | 1 | 2021 | 139 | 0.170 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 2 | 2020 | 1695 | 0.170 |
Why?
| | Cytoreduction Surgical Procedures | 1 | 2020 | 63 | 0.170 |
Why?
| | Immune System | 1 | 2021 | 177 | 0.160 |
Why?
| | Programmed Cell Death 1 Receptor | 3 | 2019 | 252 | 0.160 |
Why?
| | Chemokines, CXC | 1 | 2019 | 70 | 0.160 |
Why?
| | Bcl-2-Like Protein 11 | 1 | 2019 | 38 | 0.160 |
Why?
| | Gene Editing | 1 | 2020 | 82 | 0.160 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2020 | 392 | 0.160 |
Why?
| | Nanotechnology | 1 | 2020 | 126 | 0.150 |
Why?
| | Gene Transfer Techniques | 1 | 2020 | 169 | 0.150 |
Why?
| | CRISPR-Cas Systems | 1 | 2020 | 123 | 0.150 |
Why?
| | Interleukin-12 | 1 | 2019 | 121 | 0.150 |
Why?
| | Oligopeptides | 1 | 2000 | 273 | 0.150 |
Why?
| | Mice, Knockout | 5 | 2021 | 3020 | 0.150 |
Why?
| | Calcineurin | 1 | 2019 | 108 | 0.150 |
Why?
| | Tryptophan Oxygenase | 1 | 2018 | 34 | 0.150 |
Why?
| | Autoantigens | 1 | 2021 | 429 | 0.150 |
Why?
| | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2019 | 81 | 0.140 |
Why?
| | Genetic Therapy | 1 | 2020 | 296 | 0.140 |
Why?
| | Disease Susceptibility | 1 | 2020 | 344 | 0.140 |
Why?
| | Mutation | 5 | 2020 | 3964 | 0.140 |
Why?
| | Neoadjuvant Therapy | 1 | 2020 | 405 | 0.140 |
Why?
| | Promoter Regions, Genetic | 5 | 1997 | 1255 | 0.140 |
Why?
| | Cell Line | 2 | 2016 | 2852 | 0.140 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2019 | 211 | 0.140 |
Why?
| | Immunodominant Epitopes | 2 | 2010 | 28 | 0.130 |
Why?
| | Antigen-Presenting Cells | 1 | 2017 | 156 | 0.130 |
Why?
| | Tryptophan | 1 | 2018 | 183 | 0.130 |
Why?
| | Genetic Engineering | 2 | 2009 | 92 | 0.130 |
Why?
| | Protein Tyrosine Phosphatases | 1 | 2018 | 171 | 0.130 |
Why?
| | Transcriptional Activation | 2 | 2018 | 379 | 0.130 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2019 | 191 | 0.130 |
Why?
| | Sarcoidosis, Pulmonary | 1 | 2017 | 83 | 0.130 |
Why?
| | Spodoptera | 2 | 2021 | 40 | 0.130 |
Why?
| | Oligonucleotide Array Sequence Analysis | 2 | 2016 | 765 | 0.130 |
Why?
| | Mononuclear Phagocyte System | 1 | 2016 | 12 | 0.130 |
Why?
| | Emulsions | 1 | 2016 | 54 | 0.130 |
Why?
| | Ligands | 4 | 2018 | 665 | 0.130 |
Why?
| | Immunophenotyping | 1 | 2017 | 321 | 0.130 |
Why?
| | High-Throughput Nucleotide Sequencing | 2 | 2017 | 538 | 0.120 |
Why?
| | Lymph Nodes | 2 | 2016 | 493 | 0.120 |
Why?
| | Gene Expression Regulation | 4 | 2022 | 2615 | 0.120 |
Why?
| | Phagocytes | 1 | 2016 | 100 | 0.120 |
Why?
| | Papillomavirus Infections | 1 | 2019 | 331 | 0.120 |
Why?
| | Cell Separation | 1 | 2016 | 320 | 0.120 |
Why?
| | Lung | 3 | 2017 | 4066 | 0.120 |
Why?
| | T-Lymphocyte Subsets | 4 | 2007 | 425 | 0.110 |
Why?
| | Gene Expression Regulation, Enzymologic | 2 | 1993 | 285 | 0.110 |
Why?
| | Bronchoalveolar Lavage Fluid | 1 | 2017 | 654 | 0.110 |
Why?
| | Retinoblastoma-Binding Protein 1 | 6 | 1997 | 22 | 0.110 |
Why?
| | Ovarian Neoplasms | 1 | 2020 | 563 | 0.110 |
Why?
| | Interferon-gamma | 5 | 2011 | 790 | 0.110 |
Why?
| | Polymerase Chain Reaction | 2 | 2016 | 1061 | 0.110 |
Why?
| | E2F Transcription Factors | 6 | 1997 | 60 | 0.110 |
Why?
| | Head and Neck Neoplasms | 1 | 2019 | 617 | 0.110 |
Why?
| | Transcription Factor DP1 | 5 | 1997 | 21 | 0.100 |
Why?
| | Colorado | 2 | 2013 | 4521 | 0.100 |
Why?
| | Gene Expression Profiling | 2 | 2010 | 1770 | 0.100 |
Why?
| | Prognosis | 2 | 2020 | 4031 | 0.100 |
Why?
| | Molecular Sequence Data | 8 | 2006 | 2901 | 0.100 |
Why?
| | T-Lymphocytes, Regulatory | 3 | 2012 | 392 | 0.090 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2012 | 849 | 0.090 |
Why?
| | Transcription, Genetic | 3 | 1997 | 1458 | 0.090 |
Why?
| | Lymphoma, B-Cell | 1 | 2012 | 107 | 0.090 |
Why?
| | Hemangiosarcoma | 1 | 2010 | 22 | 0.090 |
Why?
| | Universities | 1 | 2013 | 432 | 0.080 |
Why?
| | Research | 1 | 2013 | 446 | 0.080 |
Why?
| | Carcinoma | 1 | 2011 | 237 | 0.080 |
Why?
| | Genes, MHC Class I | 1 | 2009 | 35 | 0.080 |
Why?
| | Down-Regulation | 1 | 2011 | 658 | 0.080 |
Why?
| | Mice, Inbred C57BL | 5 | 2019 | 5792 | 0.080 |
Why?
| | Neovascularization, Pathologic | 1 | 2010 | 301 | 0.080 |
Why?
| | Cross-Priming | 1 | 2008 | 18 | 0.070 |
Why?
| | CD11c Antigen | 1 | 2008 | 41 | 0.070 |
Why?
| | E2F1 Transcription Factor | 4 | 1997 | 64 | 0.070 |
Why?
| | Adjuvants, Immunologic | 1 | 2009 | 226 | 0.070 |
Why?
| | Protein Conformation | 2 | 2003 | 930 | 0.070 |
Why?
| | Xenograft Model Antitumor Assays | 2 | 2021 | 868 | 0.070 |
Why?
| | Cell Culture Techniques | 1 | 2009 | 363 | 0.060 |
Why?
| | Intramolecular Oxidoreductases | 1 | 2006 | 68 | 0.060 |
Why?
| | Hematopoietic Stem Cell Transplantation | 2 | 2021 | 614 | 0.060 |
Why?
| | Biomarkers | 1 | 2017 | 4172 | 0.060 |
Why?
| | RNA, Messenger | 2 | 1994 | 2838 | 0.060 |
Why?
| | Melanoma, Experimental | 1 | 2006 | 113 | 0.060 |
Why?
| | Drug Design | 1 | 2006 | 170 | 0.060 |
Why?
| | DNA Primers | 1 | 2006 | 514 | 0.060 |
Why?
| | Aged, 80 and over | 1 | 2017 | 7593 | 0.060 |
Why?
| | Male | 8 | 2020 | 67718 | 0.060 |
Why?
| | Amino Acid Sequence | 5 | 2018 | 2146 | 0.060 |
Why?
| | G1 Phase | 2 | 1996 | 71 | 0.060 |
Why?
| | S Phase | 2 | 1996 | 78 | 0.060 |
Why?
| | Antigens, Surface | 2 | 2001 | 154 | 0.050 |
Why?
| | Clone Cells | 2 | 2003 | 266 | 0.050 |
Why?
| | Mice, SCID | 2 | 2021 | 367 | 0.050 |
Why?
| | Cells, Cultured | 1 | 2011 | 4206 | 0.050 |
Why?
| | Liver Neoplasms, Experimental | 1 | 2003 | 31 | 0.050 |
Why?
| | 3T3 Cells | 4 | 2003 | 163 | 0.050 |
Why?
| | Genes, erbB-2 | 1 | 2003 | 28 | 0.050 |
Why?
| | Mammary Neoplasms, Experimental | 1 | 2003 | 68 | 0.050 |
Why?
| | Transplantation Chimera | 1 | 2002 | 54 | 0.050 |
Why?
| | Germ Cells | 1 | 2022 | 63 | 0.050 |
Why?
| | Molecular Conformation | 1 | 2022 | 152 | 0.050 |
Why?
| | Middle Aged | 3 | 2020 | 33355 | 0.050 |
Why?
| | Interleukin-2 | 1 | 2003 | 456 | 0.050 |
Why?
| | Transglutaminases | 1 | 2022 | 156 | 0.050 |
Why?
| | Sf9 Cells | 1 | 2021 | 9 | 0.050 |
Why?
| | Bone Marrow Cells | 1 | 2002 | 313 | 0.050 |
Why?
| | Chimerism | 1 | 2021 | 31 | 0.040 |
Why?
| | B7-1 Antigen | 1 | 2001 | 58 | 0.040 |
Why?
| | Aged | 2 | 2017 | 23798 | 0.040 |
Why?
| | Lymphocyte Subsets | 1 | 2021 | 87 | 0.040 |
Why?
| | Lymphoid Tissue | 1 | 2021 | 75 | 0.040 |
Why?
| | Immunoglobulins | 1 | 2001 | 171 | 0.040 |
Why?
| | Surface Plasmon Resonance | 1 | 2000 | 88 | 0.040 |
Why?
| | Dogs | 2 | 2012 | 411 | 0.040 |
Why?
| | Recombinant Proteins | 1 | 2003 | 1357 | 0.040 |
Why?
| | Alanine | 1 | 2000 | 153 | 0.040 |
Why?
| | Mice, Inbred NOD | 1 | 2021 | 601 | 0.040 |
Why?
| | Cyclophosphamide | 2 | 2011 | 251 | 0.040 |
Why?
| | Paraparesis, Tropical Spastic | 1 | 1998 | 3 | 0.040 |
Why?
| | Skin Neoplasms | 1 | 2006 | 853 | 0.040 |
Why?
| | Gene Products, tax | 1 | 1998 | 13 | 0.040 |
Why?
| | Models, Molecular | 1 | 2003 | 1586 | 0.040 |
Why?
| | Gene Knockdown Techniques | 1 | 2019 | 329 | 0.040 |
Why?
| | Lymphocytic Choriomeningitis | 1 | 1998 | 14 | 0.040 |
Why?
| | Antibodies, Monoclonal | 1 | 2025 | 1428 | 0.040 |
Why?
| | Receptors, Tumor Necrosis Factor, Member 25 | 1 | 2017 | 5 | 0.040 |
Why?
| | Kynurenine | 1 | 2018 | 114 | 0.030 |
Why?
| | Combined Modality Therapy | 1 | 2020 | 1241 | 0.030 |
Why?
| | Antigens, Viral | 1 | 1998 | 180 | 0.030 |
Why?
| | Mice, Nude | 1 | 2019 | 696 | 0.030 |
Why?
| | Drug Delivery Systems | 1 | 2020 | 363 | 0.030 |
Why?
| | HLA-DRB1 Chains | 1 | 2017 | 112 | 0.030 |
Why?
| | HLA Antigens | 1 | 2018 | 237 | 0.030 |
Why?
| | High-Throughput Screening Assays | 1 | 2018 | 159 | 0.030 |
Why?
| | Folic Acid Antagonists | 1 | 1996 | 9 | 0.030 |
Why?
| | Sp1 Transcription Factor | 1 | 1996 | 24 | 0.030 |
Why?
| | Enzyme Induction | 1 | 1996 | 90 | 0.030 |
Why?
| | Survival Rate | 1 | 2020 | 1980 | 0.030 |
Why?
| | Regulatory Sequences, Nucleic Acid | 1 | 1996 | 92 | 0.030 |
Why?
| | Gene Amplification | 1 | 1996 | 109 | 0.030 |
Why?
| | Clinical Trials as Topic | 1 | 2020 | 1047 | 0.030 |
Why?
| | Cadaver | 1 | 2016 | 319 | 0.030 |
Why?
| | Integrin alpha Chains | 1 | 2014 | 24 | 0.030 |
Why?
| | Interleukin-27 | 1 | 2014 | 13 | 0.030 |
Why?
| | Toll-Like Receptor 3 | 1 | 2014 | 28 | 0.030 |
Why?
| | Poly I-C | 1 | 2014 | 63 | 0.030 |
Why?
| | Toll-Like Receptor 7 | 1 | 2014 | 39 | 0.030 |
Why?
| | CD11b Antigen | 1 | 2014 | 62 | 0.030 |
Why?
| | Acute Disease | 1 | 2017 | 1008 | 0.030 |
Why?
| | DNA | 3 | 1997 | 1460 | 0.030 |
Why?
| | Cell Division | 2 | 1993 | 795 | 0.030 |
Why?
| | DNA Replication | 1 | 1996 | 242 | 0.030 |
Why?
| | Cell Cycle | 2 | 1994 | 604 | 0.030 |
Why?
| | Nuclear Proteins | 2 | 2001 | 710 | 0.030 |
Why?
| | Culture Media, Serum-Free | 1 | 1993 | 48 | 0.030 |
Why?
| | Imidazoles | 1 | 2014 | 244 | 0.030 |
Why?
| | Serum Response Factor | 1 | 1993 | 33 | 0.030 |
Why?
| | Cloning, Molecular | 3 | 2001 | 536 | 0.020 |
Why?
| | RNA Polymerase II | 1 | 1996 | 324 | 0.020 |
Why?
| | Phenotype | 1 | 2021 | 3205 | 0.020 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 2003 | 152 | 0.020 |
Why?
| | Antineoplastic Agents | 1 | 2003 | 2145 | 0.020 |
Why?
| | Membrane Glycoproteins | 1 | 2014 | 501 | 0.020 |
Why?
| | Antigens, Differentiation | 1 | 2011 | 83 | 0.020 |
Why?
| | Antineoplastic Agents, Alkylating | 1 | 2011 | 73 | 0.020 |
Why?
| | Disease Progression | 1 | 2019 | 2755 | 0.020 |
Why?
| | CTLA-4 Antigen | 1 | 2011 | 99 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2020 | 5139 | 0.020 |
Why?
| | Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2010 | 16 | 0.020 |
Why?
| | Cytokines | 1 | 2019 | 2095 | 0.020 |
Why?
| | Dimerization | 2 | 2001 | 198 | 0.020 |
Why?
| | Proteomics | 1 | 2018 | 1113 | 0.020 |
Why?
| | Statistics, Nonparametric | 1 | 2011 | 434 | 0.020 |
Why?
| | Protein Biosynthesis | 1 | 1993 | 434 | 0.020 |
Why?
| | Doxorubicin | 1 | 2012 | 368 | 0.020 |
Why?
| | ras Proteins | 1 | 2010 | 151 | 0.020 |
Why?
| | Analysis of Variance | 1 | 2011 | 1324 | 0.020 |
Why?
| | Survival Analysis | 1 | 2011 | 1320 | 0.020 |
Why?
| | DNA, Complementary | 2 | 2001 | 269 | 0.020 |
Why?
| | Protein Binding | 2 | 2006 | 2229 | 0.020 |
Why?
| | Vaccines, Attenuated | 1 | 2007 | 131 | 0.020 |
Why?
| | Binding Sites | 3 | 1997 | 1310 | 0.020 |
Why?
| | Injections, Intradermal | 1 | 2006 | 13 | 0.020 |
Why?
| | Peptide Fragments | 2 | 2003 | 708 | 0.020 |
Why?
| | Enterotoxins | 1 | 2006 | 87 | 0.020 |
Why?
| | Neoplasm Transplantation | 1 | 2006 | 256 | 0.020 |
Why?
| | Hepatitis | 1 | 2006 | 48 | 0.020 |
Why?
| | Cell Adhesion | 1 | 2006 | 467 | 0.010 |
Why?
| | Killer Cells, Natural | 1 | 2007 | 446 | 0.010 |
Why?
| | Cytotoxicity Tests, Immunologic | 1 | 2003 | 41 | 0.010 |
Why?
| | Adult | 2 | 2017 | 37821 | 0.010 |
Why?
| | Growth Inhibitors | 1 | 2003 | 43 | 0.010 |
Why?
| | Vaccines, DNA | 1 | 2003 | 32 | 0.010 |
Why?
| | Peptide Mapping | 1 | 2003 | 64 | 0.010 |
Why?
| | Cell Line, Transformed | 1 | 2003 | 145 | 0.010 |
Why?
| | Lymphocyte Culture Test, Mixed | 1 | 2002 | 50 | 0.010 |
Why?
| | Injections, Intravenous | 1 | 2003 | 208 | 0.010 |
Why?
| | Mammary Neoplasms, Animal | 1 | 2002 | 33 | 0.010 |
Why?
| | Drug Synergism | 1 | 2003 | 379 | 0.010 |
Why?
| | Mice, Inbred DBA | 1 | 2002 | 200 | 0.010 |
Why?
| | Adoptive Transfer | 1 | 2003 | 224 | 0.010 |
Why?
| | Mice, Inbred Strains | 1 | 2003 | 413 | 0.010 |
Why?
| | ZAP-70 Protein-Tyrosine Kinase | 1 | 2001 | 10 | 0.010 |
Why?
| | Transplantation Immunology | 1 | 2001 | 34 | 0.010 |
Why?
| | Programmed Cell Death 1 Ligand 2 Protein | 1 | 2001 | 15 | 0.010 |
Why?
| | Transplantation, Homologous | 1 | 2002 | 416 | 0.010 |
Why?
| | CD28 Antigens | 1 | 2001 | 53 | 0.010 |
Why?
| | Gene Library | 1 | 2001 | 117 | 0.010 |
Why?
| | Tumor Cells, Cultured | 1 | 2002 | 957 | 0.010 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2001 | 387 | 0.010 |
Why?
| | Graft vs Host Disease | 1 | 2002 | 249 | 0.010 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2001 | 188 | 0.010 |
Why?
| | Genetic Vectors | 1 | 2001 | 322 | 0.010 |
Why?
| | In Vitro Techniques | 1 | 2001 | 1108 | 0.010 |
Why?
| | Image Cytometry | 1 | 1998 | 7 | 0.010 |
Why?
| | HTLV-I Infections | 1 | 1998 | 24 | 0.010 |
Why?
| | Human T-lymphotropic virus 1 | 1 | 1998 | 28 | 0.010 |
Why?
| | HLA-A2 Antigen | 1 | 1998 | 48 | 0.010 |
Why?
| | Recombinant Fusion Proteins | 1 | 2001 | 665 | 0.010 |
Why?
| | Immunity, Active | 1 | 1998 | 10 | 0.010 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2001 | 434 | 0.010 |
Why?
| | E2F5 Transcription Factor | 1 | 1997 | 3 | 0.010 |
Why?
| | E2F4 Transcription Factor | 1 | 1997 | 8 | 0.010 |
Why?
| | Immunologic Memory | 1 | 1998 | 369 | 0.010 |
Why?
| | HeLa Cells | 1 | 1997 | 640 | 0.010 |
Why?
| | Proteins | 1 | 2001 | 1012 | 0.010 |
Why?
| | Rats | 1 | 2003 | 5676 | 0.010 |
Why?
| | Models, Genetic | 1 | 1997 | 607 | 0.010 |
Why?
| | Genes | 1 | 1994 | 230 | 0.010 |
Why?
| | Chromosome Mapping | 1 | 1994 | 523 | 0.010 |
Why?
| | Molecular Weight | 1 | 1992 | 332 | 0.010 |
Why?
| | Mutagenesis, Site-Directed | 1 | 1992 | 377 | 0.010 |
Why?
| | Transfection | 1 | 1992 | 948 | 0.000 |
Why?
| | Signal Transduction | 1 | 2001 | 5096 | 0.000 |
Why?
|
|
Slansky's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|